header advert
Results 1 - 2 of 2
Results per page:
Orthopaedic Proceedings
Vol. 104-B, Issue SUPP_7 | Pages 62 - 62
1 Jul 2022
TRENDS IN REVISION KNEE ARTHROPLASTY IN THE UK: NO EXPONENTIAL RISE OVER THE PAST 15 YEARS AND INFECTION NOW THE MOST COMMON REASON FOR REVISION
Sabah S Knight R Alvand A Beard D Price A
Full Access
View article

Abstract

Introduction

Our aim was to investigate trends in the incidence rate and main indication for revision knee replacement (rKR) over the past 15 years in the UK.

Methodology

Cross-sectional study from 2006 - 2020 using data from the National Joint Registry (NJR). Crude incidence rates were calculated using population statistics from the Office for National Statistics.

Orthopaedic Proceedings
Vol. 104-B, Issue SUPP_7 | Pages 6 - 6
1 Jul 2022
STUDY OF PERI-ARTICULAR ANAESTHETIC FOR REPLACEMENT OF THE KNEE (SPAARK): A MULTICENTRE RANDOMIZED CONTROLLED TRIAL
Hamilton T Knight R Stokes J Rombach I Cooper C Davies L Dutton S Barker K Cook J Lamb S Murray D Poulton L Wang A Strickland L Duren BV Leal J Beard D Pandit H
Full Access
View article

Abstract

Introduction

This multi-centre randomised controlled trial evaluated the clinical and cost effectiveness of liposomal bupivacaine for pain and recovery following knee replacement.

Methodology

533patients undergoing primary knee replacement were randomised to receive either liposomal bupivacaine (266mg) plus bupivacaine hydrochloride (100mg) or control (bupivacaine hydrochloride 100mg), administered at the surgical site. The co-primary outcomes were pain visual analogue score (VAS) area under the curve (AUC) 6 to 72hours and the Quality of Recovery 40 (QoR-40) score at 72hours.